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Introduction
The genus Acinetobacter includes aerobic Gram-negative 
and non-fermenting cocobacilli, which are widely spread in 
nature and might be commensal or conditionally become 
pathogenic to humans. The most common species to cause 
infections is A. baumannii, being the most frequently 
isolated from clinical specimens, followed by A. lwoffii, A. 
haemolyticus and A. johnsonii. These bacteria have been 
long considered as low-virulent strains with a reduced 
pathogenic potential, however, today they play an important 
role in colonization and infections of immunocompromised 
patients. These strains are able to colonize the skin and 
airways of patients, particularly of those admitted within 
intensive care units, where high bacterial incidence has 
been recorded (up to 75%) [1, 2].
These bacteria are recognized as disease-causing agents, 
involved in healthcare-associated infections, displaying 
high morbidity and mortality rates in critically ill patients. 
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Abstract
Background: Acinetobacter baumannii has emerged as a medically important pathogen because of the increasing number of infections produced by this 
organism over the preceding three decades and the global spread of strains with resistance to multiple antibiotic classes. Recently, a particular attention 
has been drawn to the study of the microbial persistence properties and their correlation with the rate of elimination from the source of infection, as well 
as the prognosis of the disease progression.
Material and methods: There were examined 53 strains of A. baumannii, isolated from patients with trophic ulcers. The bacteriological examination, as 
well as tests on determining both the persistence factors and the antibiotic susceptibility of the isolated strains were carried out according to the current 
method.
Results: A. baumannii strains were highly resistant to all antibiotics tested, 38 (71.7%) showed multidrug resistance. The studies regarding the persistence 
factors of A. baumannii strains,  revealed that 100%  exhibited an antilysosyme activity, 78.0% – anticomplementary activity, 73.6% – produce biofilms, 
58.5% – hemolytic activity, 28.3% and 13.2% – lecithinase and plasma coagulation activity, respectively.
Conclusions: Isolated strains showed higher level of antimicrobial resistance and multiple persistence factors. The study results proved that treatment 
of trophic ulcers is still a major problem, requiring rational monitoring and management strategies.
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These patients are more prone to germ transmission due to 
invasive medical procedures, the widespread use of a variety 
of antimicrobial agents, particularly the broad-spectrum 
ones and inappropriate infection control [3].
The infections associated with different types of immu-
nodeficiencies, virulence and antibiotic resistance of the 
Acinetobacter strains, make up 28.3% – 84.3% of mortality 
cases among patients. Currently, of particular concern is the 
selection of some A. baumannii strains that can express se-
rum bactericidal resistance to various factors and biofilm-
forming capacity, thus often being involved in bacteremia 
associated with high mortality rate (up to 75%) [3-6].
The treatment of Acinetobacter spp. infections is often 
challenging, since the bacteria show an intrinsic resistance 
to many antimicrobial agents and due to a variety of mecha-
nisms, as well as have an extraordinary ability to develop 
resistance to all classes of antimicrobials, used in the treat-
ment of gram-negative bacillus infections [4, 7].
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It is well recognized that Acinetobacter species have a 
natural resistance to cephalosporins of generations 1-2 and 
aminopenicillins. The bacterial resistance to other classes of 
antibiotics is due to various mechanisms as, enzyme inacti-
vation (penicillinases, cephalosporinases, carbapemenases, 
amino acid acetyltransferases), changes in the target sites 
(Penicillin Binding Protein), impaired membrane perme-
ability, and activating the pumps [8].
The worldwide spread of multidrug-resistant or pan-
resistant Acinetobacter baumannii strains has increased 
dramatically since 1990. The World Health Organization 
(WHO) has included these bacteria in the group of highly 
infectious agents that would spiral out of the antibiotic con-
trol [1].
According to the 2011-2014 European surveillance 
network EARS-NET (European Antimicrobial Resistance 
Surveillance – Net-work) data, the highest antibiotic resis-
tance levels of gram-negative bacilli have been reported in 
southern and eastern Europe. The highest resistance level 
was recorded in species of the genus Acinetobacter [9]. 
Acinetobacter baumannii is one of the most serious 
Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumonia, A. baumannii, Pseudomonas aeruginosa, and 
Enterobacter species (ESKAPE) organisms, as declared by the 
WHO that can escape the effect of antibacterial drugs [1].
Although trophic ulcers are a major health problem, the 
current methods of treatment are sometimes not enough 
and often lead to amputation due to misunderstanding 
regarding microbiology of these infections or methods of 
their eradication.
Although it is well known that the associated microbial 
infections might significantly worsen and delay the healing 
processes of trophic ulcers, recent research studies suggest 
that microbial biofilms highly contribute to their chroni-
city. Over 90% of chronic wounds infections are related to 
biofilms, whereas only 6% occur in acute wounds [10]. The 
protective and hostile nature of these biofilms makes the 
treatment of these infections extremely difficult. 
At present, there are evidences to suggest that the ability 
of bacteria living within cells (e.g. macrophages) and bio-
film formation are associated with persistent infections [11].
One of the causes of bacterial long-term persistence in 
the host organisms is the multiple factors that inactivate 
the antimicrobial mechanisms of the immune system. It 
is also well known that the microbial persistence potential 
determines the length of their stay in the macro-organism, 
whereas its suppression by antimicrobial drugs leads to a 
reduced infectious potential of the microorganism [12, 13].
The study was aimed to conduct and evaluate the antibi-
otic susceptibility and the persistence factors of A. bauman-
nii strains isolated from trophic ulcers.
Material and methods
The study group included 53 strains of A. baumannii, 
isolated from trophic ulcers. Solid Oxoid culture media 
were used to isolate A. baumannii: Columbia Blood Agar 
Base with 5% sheep blood, MacConkey Agar.
The identification was assessed by classical biochemical 
tests and confirmed via VITEK 2 COMPACT automatic sys-
tem.
The Kirby-Bauer disk diffusion method was used for 
antimicrobial susceptibility testing , whereas the in vi-
tro antibiotic test results were interpreted according to 
2019 EUCAST (European Committee on Antimicrobial 
Susceptibility Testing) [14].
The A. baumannii strains were tested for four classes of 
antimicrobial drugs: aminoglycosides (gentamicin, amika-
cin, tobramycin), carbapenems (meropenem, imipenem), 
fluoroquinolones (levofloxacin, ciprofloxacin) and sulfa-
nylamides (trimethoprim-sulfamethoxazole).  A.baumannii 
strains that showed resistance to three or more different 
classes of antimicrobials were classified as multidrug-resis-
tant (MDR) A. baumannii [15].
The lecithinase activity was assayed on the egg yolk salt 
agar, the hemolytic activity – on a blood agar plate, the 
plasma coagulase activity – on an inoculated culture into a 
sterile citrate plasma and the anti-lysozyme and anti-com-
plementary activity we determined according to the method 
described by Bukharin O. et al. [13, 16, 17].
Detecting the anti-complimentary activity
 The microbial suspension was inoculated on a surface 
of 1.5% agar plate; by using the bacteriological loop (the op-
tical density of the microbial suspension corresponded to 
Mac Farland turbidity standard 1.0). The petriplates were in-
oculated at a temperature of 37°C during 18-24 hr. in order 
to manifest biological properties of bacteria. Furthermore, 
the studied cultures were inactivated in chloroform vapors 
for 10 minutes, then the plates were covered with a second 
layer of 1.5 ml of agar and 1 µl complement, so that the fi-
nal concentration of the compliment corresponded to 20; 10 
and 5 UH / ml, respectively.  The petriplates were incubated 
in the inverted position at 37 ° C for 1 hour to develop the 
bacterial anti-complementary action and products of their 
activity. Then the plates were coated with a third layer of 
0.7% agar containing 0.1 ml of bacterial suspension based 
on the indicator culture of Escherichia coli ГИСК 212, which 
showed an increased sensitivity to the bactericidal action of 
complement system. The plates were incubated at 37°C for 
18-24 hr. to detect bacteria-mediated complement inacti-
vation. Anti-complementary activity was assessed by the 
presence of indicator culture growth areas surrounding the 
tested bacterial cultures, where complement inactivation 
occurred.
Detecting the anti-lysozyme activity
The tested strain was cultured on a sloping agar for 18-
24 hours at 37°C, then transferred into peptone broth and 
cultured at 37°C for 6 hours. The optical density in peptone 
broth was adjusted to 0.15, which corresponded to 1x108 
CFU/ml.
Simultaneously, the lysozyme suspension was prepared 
in peptone broth with 12.5μg /ml concentration. The use of 
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a higher concentration of lysozyme might inhibit the bacte-
rial growth, whereas lower lysozyme concentrations do not 
allow identification of this phenomenon. 
100μl of lysozyme broth was added in the wells of a 
plate, designed for enzyme-linked immunosorbent assay, 
at a 12.5μg/ml concentration, to which 25μl of microbial 
suspension was added. 100 µl of peptone broth and 25µl of 
microbial suspension were added into the control wells (2 
wells), which were incubated for 4 hours.  The optical den-
sity was measured over 2 and 4 hours. The results were read 
using an ELISA reader, whereas the optical density (OD) 
was measured at a wavelength of 600 nm (A600).
The strains were distributed according to the extent of 
this phenomenon, based on the following criteria:
1. Low expression levels of antilysosyme activity: K <0.49;
2. Mean expression levels of antilysosyme activity: K in 
the limits of 0.5-2.49;
3. High expression levels of antilysozyme activity: K> 2.5.
Determining biofilm production
 Biofilm production by isolated strains was quantitative-
ly determined using the microtiter plate method [17]. For 
the purpose of study, 150µl of peptone broth and 15 µl of 
bacterial suspension were added to a 96-well plate and ad-
justed to the 0.5 McFarland turbidity standard (respectively 
1.5 x 108 CFU/ml), which were previously prepared from 
18-24 hour bacterial culture and grown on 5% blood agar. 
The plates were coated and incubated for 24 hours at 37°C. 
Subsequently, the level of adhesion of the tested strains to 
inert substrate was determined by removing the content 
from each well and then rinsing five times with sterile sa-
line and fixing with cold methanol for 5 minutes. After re-
moving of the methanol, the dried plates were stained with 
0.1% violet crystal solution for 30 minutes. The excess stain 
was removed by washing and the stained biofilm was re-
suspended in a 33% glacial acetic acid solution. Thus the 
obtained suspensions were used to determine the optical 
density (OD), based on the spectrophotometric absorbance 
readings at 570 nm colored suspension (A570). The tests 
were performed in duplicate.
The optical density cut-off value (ODc) is defined as the 
average OD of negative control + 3x the standard deviation 
(SD) of negative control. Biofilm formation by the tested 
strains was assayed and classified according to the adsorp-
tion of the violet crystal dye. The isolates were classified into 
four categories: non-adherent (OD ≤ ODc), poor adherent 
(ODc <OD ≤ 2xODc), moderately adherent (2xODc <OD 
≤4xODc) and strongly adherent (4xODc <OD).
The reference strains A. baumannii (BAA-747) were 
used for quality control. EpiInfo 2000 was used in statistical 
data analysis.
Results and discussion
The present study assessed the antimicrobial suscepti-
bility profiles of A. baumannii strains isolated from trophic 
ulcers (fig. 1-4).
Fig. 1. Antibiotic susceptibility testing of A. baumannii 
strains to fluoroquinolones
Fig. 2. Antibiotic susceptibility testing of A. baumannii 
strains to aminoglycosides
Fig. 3. Antibiotic susceptibility testing of A. baumannii 
strains to carbapenems
Fig. 4. Antibiotic susceptibility testing of A. baumannii strains to 
sulfanylamides, TMP/SMx – trimethoprim/sulfamethoxazole
The data analysis of the previous figures revealed that 
A. baumanii strains, isolated from trophic ulcers are high-
ly resistant to most antibiotics. Of 53 strains, 38 (71.7%) 
were multidrug-resistant. Higher antibiotic susceptibility 
was registered to tobramycin 40 (75.5%) and amikacin 36 
(67.9%).
The resistance of A. baumannii strains to carbapenems 
(imipenem – 77.4% and meropenem – 52.8%) is of major 
concern. The World Health Organization stated that car-
bapenem-resistant Acinetobacter baumannii infections have 
become a major public health challenge and a serious health 
threat in future [18].
The present study also assessed one of the persistence 
factors of A. baumannii strains viz. the anti-lysozyme activ-
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ity. The anti-lysozyme activity (the ability of microorgan-
isms to deactivate muramidase, which is an essential link 
in non-specific resistance) is very common among various 
isolates [19]. Of the 53 A. baumannii strains isolated from 
trophic ulcers, 53 (100%) showed an anti-lysozyme activity. 
A high expression level of anti-lysozyme activity (K> 2.5) 
was recorded in 16 (30.2%) strains, a mean expression level 
(K0.5-2.49) – 24 (45.3%) strains and a low expression level 
(K <0.49) was revealed in 13 (24.5%) of strains.
Hemolysin was another persistence factor studied, which 
acts as an exotoxin that may lead to chronicity of various in-
fectious process [20]. Hemolytic activity was recorded in 31 
(58.5%) A. baumannii strains isolated from trophic ulcers.
Lecithinase was present in 15 (28.3%) A. baumanii 
strains and plasmocoagulase – in only 7 (13.2%) strains. 
Lecithinase is an exoenzyme that acts upon phospholipids 
(lecithin) within the muscle fiber membrane, erythrocytes 
and other cells. Plasmocoagulase is a proteolytic enzyme 
that leads to septic thrombi formation and exerts an anti-
phagocytic effect by spreading within the body. These en-
zymes are aggressive factors for the microorganisms [20].
The ability to deactivate the complement system of the 
macroorganism leads to a microbial persistence within the 
infectious focus, which develops into chronic processes 
[19]. Lipid A and serine protease of A. baumannii exhibit 
an anticomplementary activity, thus providing a long-term 
bacterial survival inside the host organism [21, 22].
Of the 53 strains studied, 50 (94.3%) showed anti-comple-
mentary activity, of which 39 (78.0%) strains inactivated the 
complement at a concentration greater than 15 CH50 / ml, 
8 (16.0%) – at a concentration of 5-15 CH50 / ml and 6 
(12.0%) – at a concentration of 5 CH50 / ml. Only 3 strains 
(5.7%) did not inactivate the complement.
Biofilm-forming ability of A. baumannii clinical strains 
is crucial for their survival inside the macroorganism (even 
in antibiotic treatment) [23].
Of the 53 A. baumannii strains tested – 39 (73.6%) pro-
duced detectable biofilms. As regarding the biofilm status, 
15 (38.5%) of the isolates were determined as strong bio-
film forming, 6 (15.4%) – moderate biofilm forming and 
18 (46.1%) – produced weak biofilms, out of the 39 strains. 
Similar data have been reported by a series of studies, which 
reported that over 74% of A. baumannii clinical strains pro-
duced biofilms [24, 25].
The correlation between the biofilm formation ability 
and MDR strains was also studied (tab. 1). Of the 38 MDR 
A. baumannii strains – 14 (36.8%) produced strong biofilms, 
4 (10.5%) – moderate biofilms, 17 (44.7%) – weak biofilms 
and 3 (7.9%) – produced no biofilms.
Conclusions
The research findings underline the importance of an 
effective surveillance of antimicrobial resistance of A. bau-
mannii strains, thus suggesting the appropriate use of anti-
microbials in order to prevent the emergence of bacterial 
resistance to these specific drugs. 
The present study proved that the most expressed patho-
genicity factors in A. baumannii strains, isolated from tro-
phic ulcers, are lysozyme inactivation, complement and bio-
film formation. The assessment of virulence and persistence 
factors will help the practitioners to effectively manage these 
infections, providing a more effective control of appropriate 
antimicrobials and thus resulting in a reduced mortality and 
morbidity rates in patients.
The study results justify the development of new strate-
gies for the prevention and treatment of A. baumannii infec-
tions. 
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